HPM1 Antibody

What are the optimal storage conditions for maintaining HPM1 antibody activity?

HPM1 antibodies should be stored at -20°C for long-term preservation. They remain stable for approximately one year after shipment when maintained at this temperature. For optimal preservation of antibody function, the recommended storage buffer contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. This formulation helps prevent degradation and maintains antibody stability . Aliquoting is generally unnecessary for -20°C storage unless frequent freeze-thaw cycles are anticipated, which can compromise antibody performance. Smaller packaging sizes (20μl) commonly contain 0.1% BSA as a stabilizer to further enhance shelf-life .

What is the recommended protocol for Western Blot applications using HPM1 antibody?

For Western Blot applications, HPM1 antibody should be diluted within a range of 1:500-1:2000, with the optimal dilution determined through titration for each specific experimental system . The following protocol elements are critical:

• Sample preparation: Properly lyse cells using a compatible buffer that preserves protein integrity

• Protein separation: Separate proteins using standard SDS-PAGE techniques

• Transfer: Transfer proteins to a PVDF or nitrocellulose membrane

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1-2 hours

• Primary antibody incubation: Apply the diluted HPM1 antibody and incubate overnight at 4°C

• Washing: Perform sequential washes with TBST buffer

• Secondary antibody application: Apply appropriate HRP-conjugated secondary antibody

• Detection: Visualize using chemiluminescence detection methods

The expected molecular weight observed on Western blots should be approximately 39-42 kDa, which aligns with the calculated molecular weight of 39 kDa .

What cell lines have been validated for HPM1 antibody applications?

HPM1 antibody has been validated in multiple human cell lines for various applications, ensuring reliable performance across experimental systems. For Western Blot applications, positive detection has been confirmed in HeLa cells, A375 cells, HEK-293 cells, and Raji cells . For immunoprecipitation (IP) procedures, HEK-293 cells have been specifically validated as suitable experimental models . Immunofluorescence and immunocytochemistry applications have demonstrated positive results with MCF-7 cells, HeLa cells, and HepG2 cells . This cross-application validation provides researchers with flexibility in experimental design while maintaining confidence in antibody performance.

How can epitope mapping be performed to characterize HPM1 antibody binding sites?

Epitope mapping for HPM1 antibody requires a systematic approach utilizing multiple complementary techniques:

• Peptide Array Analysis: Synthesize overlapping peptides spanning the target protein sequence. Incubate the HPM1 antibody with the peptide array and detect binding through ELISA-based methods to identify linear epitopes.

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS): Compare deuterium uptake patterns of the target protein in the presence and absence of HPM1 antibody. Regions showing protection from deuterium exchange likely represent antibody binding sites.

• Alanine Scanning Mutagenesis: Create a panel of protein variants with alanine substitutions at different residues. Test each variant's binding to HPM1 antibody to identify critical amino acids within the epitope.

• X-ray Crystallography: For definitive structural characterization, crystallize the antibody-antigen complex and determine the three-dimensional structure, providing atomic-level detail of the binding interface.

• Competition Assays: Perform competition experiments with other antibodies of known epitopes to map relative binding locations.

This multi-technique approach is necessary because single methods may miss conformational epitopes or provide incomplete binding site information .

What considerations are important when designing cross-reactivity studies for HPM1 antibody?

When designing cross-reactivity studies for HPM1 antibody, researchers should implement a comprehensive validation strategy:

• Species Cross-Reactivity Assessment: HPM1 antibody shows reactivity with human, mouse, and rat samples, but validation across additional species requires systematic testing with appropriate positive and negative controls .

• Tissue Panel Testing: Evaluate binding patterns across diverse tissue types, particularly focusing on tissues with high target protein expression and potential off-target binding sites.

• Western Blot Validation: Perform Western blot analysis using tissue lysates from multiple species to confirm specificity and identify potential cross-reactive proteins based on molecular weight patterns.

• Immunohistochemistry Comparison: Compare staining patterns across multiple species' tissue sections to evaluate conservation of epitope recognition.

• Knockout/Knockdown Controls: Include samples from knockout models or knockdown experiments as critical negative controls to definitively validate specificity.

• Peptide Competition: Perform blocking experiments with the immunizing peptide to confirm binding specificity and epitope recognition.

This systematic approach ensures comprehensive characterization of antibody specificity across experimental systems and prevents misinterpretation of results due to unidentified cross-reactivity .

How can HPM1 antibody be utilized in multiplex immunoassays for complex sample analysis?

Multiplex immunoassays incorporating HPM1 antibody require careful optimization to maintain sensitivity and specificity when analyzing complex samples:

• Antibody Labeling Strategy: Direct labeling of HPM1 antibody with fluorophores (Alexa Fluor dyes, quantum dots) or biotin must be optimized to maintain binding affinity. The recommended labeling ratio is typically 2-4 fluorophore molecules per antibody to prevent steric hindrance.

• Panel Design Considerations:

  • Validate the absence of spectral overlap when using multiple fluorophores

  • Confirm no cross-reactivity between antibodies in the multiplex panel

  • Stagger antibody concentrations based on target abundance

• Sample Preparation Optimization:

  • Homogenization techniques for tissue samples must be standardized

  • Blocking protocols should be optimized to minimize background

  • Sample dilution series should be tested to establish optimal concentration ranges

• Data Analysis Approach:

  • Implement appropriate normalization methods

  • Establish clear positive and negative thresholds

  • Utilize appropriate statistical approaches for multiplex data interpretation

• Validation Strategy:

  • Compare results with single-plex assays to confirm no interference

  • Include appropriate isotype controls

  • Validate using complementary techniques (Western blot, ELISA)

This methodical approach ensures robust and reproducible results when implementing HPM1 antibody in complex multiplex experimental systems .

What optimization strategies should be employed for immunoprecipitation using HPM1 antibody?

For successful immunoprecipitation with HPM1 antibody, researchers should implement the following optimization strategies:

• Antibody Titration: The recommended starting range is 0.5-4.0 μg of HPM1 antibody per 1.0-3.0 mg of total protein lysate . Titration experiments should be performed to determine the optimal antibody concentration for specific sample types.

• Lysis Buffer Selection:

  • For membrane proteins: Use buffers containing 1% NP-40 or 1% Triton X-100

  • For nuclear proteins: Consider RIPA buffer with appropriate protease inhibitors

  • Always supplement with protease/phosphatase inhibitor cocktails

• Pre-clearing Strategy: Pre-clear lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding before adding HPM1 antibody.

• Incubation Conditions:

  • Primary incubation: 4-16 hours at 4°C with gentle rotation

  • Bead binding: 1-2 hours at 4°C with protein A/G beads

  • Washing: Minimum of 4-5 washes with decreasing salt concentrations

• Elution Method Selection:

  • Denaturing: SDS sample buffer at 95°C for 5 minutes

  • Non-denaturing: Glycine buffer (pH 2.5-3.0) followed by immediate neutralization

  • Native complex recovery: Competitive elution with excess immunizing peptide

• Validation Controls:

  • Input control: 5-10% of pre-IP lysate

  • Negative control: Isotype-matched control antibody

  • IP efficiency control: Western blot of supernatant post-IP

This systematic approach maximizes recovery of target protein while minimizing background contamination in IP experiments with HPM1 antibody .

What factors influence immunofluorescence staining quality when using HPM1 antibody?

Optimizing immunofluorescence experiments with HPM1 antibody requires attention to several critical variables:

• Fixation Method Selection:

  • Paraformaldehyde (4%): Preserves morphology but may mask some epitopes

  • Methanol/acetone: Better for some intracellular epitopes but compromises membrane structures

  • Glyoxal: Alternative for preserving both structure and epitope accessibility

• Permeabilization Protocol:

  • Triton X-100 (0.1-0.5%): Suitable for nuclear proteins

  • Saponin (0.1-0.5%): Milder for cytoplasmic proteins

  • Digitonin (10-50 μg/mL): Selective for plasma membrane permeabilization

• Blocking Strategy:

  • Serum (5-10%): Match to secondary antibody host species

  • BSA (3-5%): Alternative protein blocker

  • Commercial blocking solutions: Consider for high background issues

• Antibody Dilution Range:

  • HPM1 antibody should be used at 1:20-1:200 dilution for IF/ICC applications

  • Titration experiments are essential for each cell type and fixation method

• Incubation Parameters:

  • Temperature: 4°C (overnight) vs. room temperature (1-2 hours)

  • Humidity control: Essential to prevent sample drying

  • Washing stringency: Affects signal-to-noise ratio

• Mounting Media Selection:

  • Anti-fade properties: Critical for confocal microscopy

  • Hardening vs. non-hardening: Depends on imaging timeframe

  • DAPI inclusion: Consider separate DAPI staining for better control

• Controls Implementation:

  • Peptide competition: Confirms specificity

  • Secondary-only control: Establishes background level

  • Positive control: Validates staining protocol

Careful optimization of these parameters ensures consistent, high-quality immunofluorescence results with HPM1 antibody across experimental systems .

What methods can be employed to quantitatively measure HPM1 antibody binding affinity?

Accurate quantification of HPM1 antibody binding affinity requires multiple complementary biophysical techniques:

• Surface Plasmon Resonance (SPR):

  • Immobilize target protein on sensor chip surface

  • Flow HPM1 antibody at varying concentrations (typically 0.1-100 nM)

  • Measure association (ka) and dissociation (kd) rate constants

  • Calculate equilibrium dissociation constant (KD = kd/ka)

  • Typical high-affinity antibodies exhibit KD values in the 10⁻⁸ to 10⁻¹⁰ M range

• Bio-Layer Interferometry (BLI):

  • Alternative to SPR with similar working principles

  • Offers higher throughput capability

  • Requires less sample volume than traditional SPR

• Isothermal Titration Calorimetry (ITC):

  • Measures heat released/absorbed during binding

  • Provides complete thermodynamic profile (ΔH, ΔS, ΔG)

  • Generally requires higher protein concentrations (μM range)

• Microscale Thermophoresis (MST):

  • Measures changes in thermophoretic mobility upon binding

  • Requires fluorescent labeling of one binding partner

  • Works well with small sample volumes

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Indirect measurement through titration curves

  • Calculate apparent KD from half-maximal binding

  • Provides functional affinity in application-relevant format

These complementary approaches provide comprehensive characterization of HPM1 antibody binding properties in different experimental contexts .

How can nonspecific binding be minimized in Western blot applications using HPM1 antibody?

Reducing nonspecific binding in Western blot applications with HPM1 antibody requires systematic optimization:

• Blocking Optimization:

  • Test multiple blocking agents: 5% non-fat milk, 3-5% BSA, commercial blockers

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

  • Add 0.1-0.3% Tween-20 to blocking solution for membrane proteins

• Antibody Dilution Refinement:

  • Start with manufacturer's recommended range (1:500-1:2000)

  • Prepare a dilution series to identify optimal concentration

  • Dilute antibody in fresh blocking solution rather than plain buffer

• Washing Protocol Enhancement:

  • Increase wash frequency (5-6 washes vs. standard 3)

  • Extend wash duration (10 minutes per wash)

  • Use TBST with higher Tween-20 concentration (0.1-0.3%)

• Sample Preparation Considerations:

  • Ensure complete protein denaturation (boil samples for 5-10 minutes)

  • Centrifuge samples after boiling to remove insoluble material

  • Include reducing agent (DTT or β-mercaptoethanol) in sample buffer

• Membrane Handling Techniques:

  • Never allow membrane to dry during procedure

  • Use consistent gentle agitation during all incubations

  • Handle membrane with forceps to avoid contamination

• Secondary Antibody Selection:

  • Use highly cross-adsorbed secondary antibodies

  • Consider fluorescent secondaries for lower background

  • Titrate secondary antibody independently of primary

• Additional Considerations:

  • Pre-incubate antibody with blocking solution before application

  • Consider alternative membrane types (PVDF vs. nitrocellulose)

  • Implement overnight primary antibody incubation at 4°C rather than shorter incubation at room temperature

Implementation of these techniques significantly improves signal-to-noise ratio in Western blot applications with HPM1 antibody .

What validation experiments should be performed to confirm HPM1 antibody specificity?

Comprehensive validation of HPM1 antibody specificity requires multiple complementary approaches:

• Genetic Knockout/Knockdown Validation:

  • CRISPR/Cas9 knockout cell lines

  • siRNA/shRNA knockdown with >80% target reduction

  • Comparison of signal in wild-type vs. modified cells across applications

• Peptide Competition Assays:

  • Pre-incubate antibody with 5-10× molar excess of immunizing peptide

  • Run competitive and non-competitive samples side-by-side

  • Specific signals should be substantially reduced/eliminated

• Mass Spectrometry Verification:

  • Immunoprecipitate target protein using HPM1 antibody

  • Analyze immunoprecipitated proteins by LC-MS/MS

  • Confirm presence of target protein and identify any co-precipitating proteins

• Multi-antibody Comparison:

  • Test multiple antibodies targeting different epitopes of the same protein

  • Compare staining/binding patterns across techniques

  • Consistent patterns across antibodies increase confidence in specificity

• Recombinant Protein Controls:

  • Test antibody against purified recombinant protein

  • Include related family members to assess cross-reactivity

  • Determine binding affinity and specificity quantitatively

• Immunohistochemistry Correlation:

  • Compare IHC staining patterns with known expression profiles

  • Assess subcellular localization consistency with protein function

  • Evaluate staining in multiple tissue types with varying expression levels

• Cross-species Reactivity Assessment:

  • Test against mouse and rat samples in addition to human

  • Compare sequence homology in epitope regions

  • Verify consistent binding in conserved regions

This multi-faceted validation approach ensures high confidence in experimental results generated using HPM1 antibody across diverse research applications .

How can researchers troubleshoot poor signal in ELISA applications using HPM1 antibody?

Addressing poor signal in ELISA applications with HPM1 antibody requires systematic troubleshooting:

• Antibody Functionality Verification:

  • Confirm antibody activity in alternative applications (Western blot)

  • Test freshly prepared antibody dilution

  • Verify antibody hasn't expired or undergone excessive freeze-thaw cycles

• Antigen Immobilization Optimization:

  • Test different coating buffers (carbonate pH 9.6, PBS pH 7.4)

  • Increase coating concentration (typically 1-10 μg/mL)

  • Extend coating incubation (overnight at 4°C)

  • Consider alternative plate types (high vs. medium binding)

• Blocking Protocol Refinement:

  • Test different blocking agents (BSA, casein, commercial blockers)

  • Extend blocking time (2 hours at room temperature)

  • Ensure freshly prepared blocking solution

• Antibody Concentration Adjustment:

  • Perform titration series (typical range: 0.1-10 μg/mL)

  • Reduce dilution factor by 2-5× from recommended Western blot dilution

  • Optimize incubation time (1-2 hours at room temperature vs. overnight at 4°C)

• Detection System Enhancement:

  • Verify secondary antibody reactivity and dilution

  • Consider more sensitive substrates (chemiluminescent vs. colorimetric)

  • Extend substrate development time

  • Test avidin-biotin amplification systems

• Sample Handling Considerations:

  • Minimize freeze-thaw cycles of antigen

  • Verify pH and ionic strength of buffers

  • Include protease inhibitors in sample preparation

  • Consider native vs. denatured protein conformation

• Protocol Modifications:

  • Increase incubation temperature (room temperature vs. 37°C)

  • Implement gentle shaking during incubations

  • Add 0.05% Tween-20 to wash buffer to reduce background

  • Consider sandwich ELISA format if direct coating is ineffective

Systematic application of these troubleshooting approaches identifies and resolves factors limiting ELISA performance with HPM1 antibody .

How can HPM1 antibody be adapted for high-throughput screening applications?

Adapting HPM1 antibody for high-throughput screening requires several methodological adjustments:

• Miniaturization Strategies:

  • Transition to 384 or 1536-well plate formats

  • Reduce assay volumes to 10-25 μL per well

  • Optimize antibody concentration for miniaturized format (typically 2-3× higher than standard assays)

  • Implement automated liquid handling systems for consistency

• Assay Format Adaptation:

  • Homogeneous (no-wash) formats reduce variability

  • Time-resolved fluorescence resonance energy transfer (TR-FRET)

  • AlphaScreen/AlphaLISA proximity-based detection

  • Label-free detection systems (e.g., bioimpedance, SPR imaging)

• Readout Technology Selection:

  • Fluorescence polarization for binding studies

  • Bioluminescence resonance energy transfer (BRET) for protein interactions

  • High-content imaging for subcellular localization analysis

  • Multiplexed bead-based assays for pathway analysis

• Automation Integration:

  • Liquid handling robotics for precise dispensing

  • Automated incubation systems with temperature control

  • Integrated plate washing and reading systems

  • Data analysis pipeline development

• Assay Validation Parameters:

  • Z' factor >0.5 indicates excellent assay quality

  • Signal-to-background ratio >5:1

  • Coefficient of variation <15% across plates

  • DMSO tolerance testing (typically up to 1%)

• Screening Library Considerations:

  • Compound interference assessment

  • Counter-screen development

  • Dose-response confirmation of primary hits

  • Orthogonal assay validation

This systematic approach enables adaptation of HPM1 antibody-based assays to high-throughput screening platforms while maintaining sensitivity and specificity .

What are the considerations for developing multiplexed flow cytometry panels incorporating HPM1 antibody?

Developing robust multiplexed flow cytometry panels with HPM1 antibody requires attention to several critical factors:

• Panel Design Strategy:

  • Assign brightest fluorochromes to lowest-expressed targets

  • Separate fluorochromes with spectral overlap on different markers

  • Consider antigen co-expression patterns when selecting markers

  • Balance surface and intracellular markers across fluorochromes

• Fluorochrome Selection Criteria:

  • Brightness ranking: PE > APC > PE-Cy7 > FITC > Pacific Blue

  • Spillover spreading matrix calculation for optimal combinations

  • Tandem dye stability assessment under experimental conditions

  • Photobleaching considerations for complex staining protocols

• Antibody Performance Validation:

  • Single-color controls for each fluorochrome

  • Fluorescence-minus-one (FMO) controls for gating

  • Titration of HPM1 antibody in multiplexed format

  • Temperature sensitivity testing (4°C vs. room temperature staining)

• Protocol Optimization Considerations:

  • Fixation impact on epitope availability

  • Buffer compatibility across antibodies

  • Incubation timing and temperature standardization

  • Sequential vs. simultaneous staining for intracellular targets

• Instrument Setup Requirements:

  • PMT voltage optimization for each channel

  • Appropriate compensation controls

  • Application settings for longitudinal studies

  • Quality control particles for day-to-day standardization

• Data Analysis Approach:

  • Manual vs. automated gating strategies

  • Dimensionality reduction techniques (tSNE, UMAP)

  • Clustering algorithms for population identification

  • Batch effect correction methods

This systematic approach ensures optimal performance of HPM1 antibody in complex multiplexed flow cytometry panels, maximizing data quality and experimental reproducibility .